Literature DB >> 15672531

Cryptosporidium felis and C. meleagridis in persons with HIV, Portugal.

Olga Matos, Margarida Alves, Lihua Xiao, Vitaliano Cama, Francisco Antunes.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15672531      PMCID: PMC3323403          DOI: 10.3201/eid1012.031068

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Cryptosporidium, a pathogenic protozoan parasite with a worldwide distribution, causes diarrheal illness in humans and animals. The parasite can be transmitted from human to human through fecal-oral contact (household contact and nosocomial transmission), sexual contact, ingestion of contaminated food or water, and contact with infected animals. Molecular diagnostic methods indicate that Cryptosporidium parvum and C. hominis are the major causes of cryptosporidiosis in humans, and other Cryptosporidium species can be associated with human infection (–). In Portugal, patients with AIDS have an 8% prevalence rate of cryptosporidiosis () with C. parvum and C. hominis as the etiologic agents, even though other Cryptosporidium species were found in these patients (,,). This study characterizes clinical manifestations of infections with unusual two different Cryptosporidium species isolated from seven patients and demonstrates that these species can cause life-threatening disease. Cryptosporidiosis was diagnosed in 40 patients from 1994 through 2002. All patients were serologically positive for HIV-1 and had diarrhea (at least two loose stools per day) when diagnosed with cryptosporidiosis. Demographic, clinical, and immunologic data were obtained from each patient's records. Cryptosporidium oocysts were identified by light microscopy after concentration from fecal material by a modified water-ether sedimentation method followed by the modified Ziehl-Neelsen staining (). The intensity of infection was quantified before molecular analysis by scoring the number of oocysts counted per microscopic field (under a 20x objective) of 50-μL volume of concentrated stool sample as + (1–5 oocysts), ++ (6–10 oocysts), +++ (11–15 oocysts), or ++++ (>15 oocysts). Genetic characterization of the isolates was based on polymerase chain reaction–restriction fragment length polymorphism analysis of the small subunit rRNA gene (,). The molecular analysis showed that 22 patients (55%) were infected with C. parvum, 11 (27.5%) were infected with C. hominis, 4 (10%) were infected with C. felis, and 3 (7.5%) were infected with C. meleagridis. Of the four patients infected with C. felis, three (75%) showed low (+) and one (25%) showed moderate (++) oocyst loads. All three (100%) patients infected with C. meleagridis showed low oocyst loads (+). In contrast, of the 22 patients infected with C. parvum, 9 (41%) showed low oocyst loads (+), 3 (14%) showed moderate oocyst loads (++), 3 (14%) showed high oocyst loads (+++), and 7 (32%) showed very high (++++) oocyst loads. Similarly, of the 11 patients infected with C. hominis, 2 (18%) had low oocyst loads (+), and 3 (27%) each had moderate (++), high (+++), or very high (++++) oocyst loads. Five of the seven patients infected with C. felis and C. meleagridis were men and two were women; the median age of patients was 31 years (7–44 years). In this group of HIV-positive patients, three were heterosexual persons, two were homosexual persons, one was an intravenous drug user, and one acquired HIV infection through vertical transmission. Of the seven patients, all showed a range of clinical manifestations of infection, including transient diarrhea, chronic diarrhea, dehydration, and cachexia. Five (71%) of the patients spontaneously recovered, and two (29%) of the patients died. The median CD4+ count/mm3 was 20 (range 18–213). All of the seven patients were prescribed antiretroviral therapy, but one of the patients did not adhere to the treatment. Two of the three patients infected with C. meleagridis died of cryptosporidiosis. Information on the risk factors for acquiring Cryptosporidium infection was available for one patient, the child infected with C. felis, who had contact with cats at home. No other potential intestinal pathogens were detected in the feces of these patients at the time of the cryptosporidiosis diagnosis. Twenty-two of the 33 patients infected with C. parvum and C. hominis were men and 11 were women; the median age of patients was 32 years (7–58 years). Sixteen patients were intravenous drug users, 5 patients were heterosexual persons, 1 patient was a homosexual person, and 2 patients acquired HIV infection through vertical transmission; the remaining 9 patients had no HIV-exposure history information. Eighteen of the 22 patients infected with C. parvum showed a range of clinical manifestations of illness with transient diarrhea, chronic diarrhea, dehydration, and cachexia. Twelve (67%) of the patients spontaneously recovered, and 6 (33%) of the patients died. Information on CD4+ count/mm3 was available for 13 of the 22 patients with a median count of 20 (range 3–250). Information on the outcome of the patients infected with C. hominis was available for 10 of the 11 patients. All of the 10 patients showed a range of clinical manifestations of infection, including transient diarrhea, chronic diarrhea, dehydration, and cachexia. Seven (70%) of the patients spontaneously recovered, and 3 (30%) of the patients died. The median CD4+ count/mm3 was 20 (range 6–40). Most reports on infections with unusual Cryptosporidium species in humans give a brief description of the genotyping results, leaving the clinical importance of these species uncertain. Unusual Cryptosporidium species can cause disease (symptomatic infection) and death. C. felis and C. meleagridis infections showed low oocyst shedding (all seven patients had low to moderate oocyst loads in samples). On the contrary, C. parvum produced similar clinical manifestations but showed higher oocyst shedding; 46% had high to very high parasite loads. C. hominis infections had parasite loads even higher than C. parvum infections; 54% of patients had high to very high parasite loads. In immunocompetent persons, C. hominis infections produce higher oocyst loads in feces than infections caused by C. parvum or zoonotic species (,). The transmission route for the unusual Cryptosporidium species is unclear. Because human infection by unusual Cryptosporidium species is less common, the principal transmission route for these parasites is likely through direct contact with infected animals. In our study, one of the four immunocompromised patients with C. felis was a child who had been in close contact with cats at home. No data on animal contact were available for other patients infected with unusual Cryptosporidium species. Cats are found in many homes with no evidence of cryptosporidiosis; therefore, it is difficult to attribute the occasional human C. felis infection to contamination by cats. Careful epidemiologic studies are needed to elucidate the transmission route of human infections with unusual Cryptosporidium species.
  9 in total

1.  PCR-RFLP analysis of Cryptosporidium parvum isolates from HIV-infected patients in Lisbon, Portugal.

Authors:  M Alves; O Matos; F Spano; F Antunes
Journal:  Ann Trop Med Parasitol       Date:  2000-04

2.  Multilocus PCR-RFLP analysis of Cryptosporidium isolates from HIV-infected patients from Portugal.

Authors:  M Alves; O Matos; F Antunes
Journal:  Ann Trop Med Parasitol       Date:  2001-09

3.  Multilocus genotyping of Cryptosporidium isolates from human HIV-infected and animal hosts.

Authors:  M Alves; O Matos; I Pereira Da Fonseca; E Delgado; A M Lourenço; F Antunes
Journal:  J Eukaryot Microbiol       Date:  2001       Impact factor: 3.346

4.  Identification of 5 types of Cryptosporidium parasites in children in Lima, Peru.

Authors:  L Xiao; C Bern; J Limor; I Sulaiman; J Roberts; W Checkley; L Cabrera; R H Gilman; A A Lal
Journal:  J Infect Dis       Date:  2000-12-20       Impact factor: 5.226

5.  Molecular characterization of Cryptosporidium isolates obtained from humans in France.

Authors:  K Guyot; A Follet-Dumoulin; E Lelièvre; C Sarfati; M Rabodonirina; G Nevez; J C Cailliez; D Camus; E Dei-Cas
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

6.  Molecular epidemiological analysis of Cryptosporidium spp. in the United Kingdom: results of genotyping Cryptosporidium spp. in 1,705 fecal samples from humans and 105 fecal samples from livestock animals.

Authors:  J McLauchlin; C Amar; S Pedraza-Díaz; G L Nichols
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

7.  Genetic characterization of Cryptosporidium strains from 218 patients with diarrhea diagnosed as having sporadic cryptosporidiosis.

Authors:  J McLauchlin; S Pedraza-Díaz; C Amar-Hoetzeneder; G L Nichols
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

Review 8.  Cryptosporidium taxonomy: recent advances and implications for public health.

Authors:  Lihua Xiao; Ronald Fayer; Una Ryan; Steve J Upton
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Prevalence of cryptosporidiosis in AIDS patients with diarrhoea in Santa Maria Hospital, Lisbon.

Authors:  O Matos; A Tomás; P Aguiar; D Casemore; F Antunes
Journal:  Folia Parasitol (Praha)       Date:  1998       Impact factor: 2.122

  9 in total
  16 in total

1.  Presence of Cryptosporidium spp. and Giardia duodenalis in drinking water samples in the north of Portugal.

Authors:  André Almeida; Maria João Moreira; Sónia Soares; Maria de Lurdes Delgado; João Figueiredo; Elisabete Silva; António Castro; José Manuel Correida Da Cosa
Journal:  Korean J Parasitol       Date:  2010-03-18       Impact factor: 1.341

2.  Cryptosporidium meleagridis: infectivity in healthy adult volunteers.

Authors:  Cynthia L Chappell; Pablo C Okhuysen; Rebecca C Langer-Curry; Donna E Akiyoshi; Giovanni Widmer; Saul Tzipori
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

3.  Biological and genetic characterization of Cryptosporidium spp. and Giardia duodenalis isolates from five hydrographical basins in northern Portugal.

Authors:  André Almeida; Maria João Moreira; Sónia Soares; Maria de Lurdes Delgado; João Figueiredo; Elisabete Silva Magalhães; António Castro; Alexandra Viana Da Costa; José Manuel Correia da Costa
Journal:  Korean J Parasitol       Date:  2010-06-17       Impact factor: 1.341

4.  Distribution of Cryptosporidium subtypes in humans and domestic and wild ruminants in Portugal.

Authors:  Margarida Alves; Lihua Xiao; Francisco Antunes; Olga Matos
Journal:  Parasitol Res       Date:  2006-03-22       Impact factor: 2.289

5.  Global distribution, public health and clinical impact of the protozoan pathogen cryptosporidium.

Authors:  Lorenza Putignani; Donato Menichella
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-07-14

6.  Cryptosporidium species and subtypes and clinical manifestations in children, Peru.

Authors:  Vitaliano A Cama; Caryn Bern; Jacqueline Roberts; Lilia Cabrera; Charles R Sterling; Ynes Ortega; Robert H Gilman; Lihua Xiao
Journal:  Emerg Infect Dis       Date:  2008-10       Impact factor: 6.883

7.  Human intestinal parasites.

Authors:  Rashidul Haque
Journal:  J Health Popul Nutr       Date:  2007-12       Impact factor: 2.000

8.  Cryptosporidium felis infection, Spain.

Authors:  María Teresa Llorente; Antonio Clavel; Marzo Varea; María Pilar Goñi; Juan Sahagún; Susana Olivera
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883

9.  Unique Cryptosporidium population in HIV-infected persons, Jamaica.

Authors:  Wangeci Gatei; Donnett Barrett; John F Lindo; Denise Eldemire-Shearer; Vitaliano Cama; Lihua Xiao
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

10.  Infectivity of Cryptosporidium andersoni and Cryptosporidium muris to normal and immunosuppressive cynomolgus monkeys.

Authors:  Koichi Masuno; Yasuhiro Fukuda; Masahito Kubo; Ryo Ikarashi; Takeshi Kuraishi; Shosaku Hattori; Junpei Kimura; Chieko Kai; Tokuma Yanai; Yutaka Nakai
Journal:  J Vet Med Sci       Date:  2013-10-16       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.